| scholarly article | Q13442814 |
| P50 | author | Richard Lee | Q16735186 |
| P2093 | author name string | K M George | |
| D Chatterjee | |||
| P L Small | |||
| J Hayman | |||
| G Gunawardana | |||
| D Welty | |||
| P433 | issue | 5403 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium ulcerans | Q141154 |
| virulence | Q1460232 | ||
| P304 | page(s) | 854-7 | |
| P577 | publication date | 1999-02-05 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence | |
| P478 | volume | 283 |
| Q36314364 | "Mycobacterium ulcerans subsp. shinshuense" isolated from a skin ulcer lesion: identification based on 16S rRNA gene sequencing |
| Q40130491 | A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. |
| Q36030070 | A Community Based Study on the Mode of Transmission, Prevention and Treatment of Buruli Ulcers in Southwest Cameroon: Knowledge, Attitude and Practices |
| Q57776797 | A Diverted Total Synthesis of Mycolactone Analogues: An Insight into Buruli Ulcer Toxins |
| Q24548793 | A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells |
| Q35903981 | A Sero-epidemiological Approach to Explore Transmission of Mycobacterium ulcerans |
| Q42799618 | A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice |
| Q34406831 | A case of cutaneous tuberculosis in a Buruli ulcer-endemic area |
| Q42469123 | A molecular approach to identifying the natural prey of the African creeping water bug Naucoris, a potential reservoir of Mycobacterium ulcerans |
| Q24524154 | A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin |
| Q45306722 | A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase |
| Q37234097 | A novel mycolactone toxin obtained by biosynthetic engineering |
| Q35163364 | A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis |
| Q64121218 | A survey on Mycobacterium ulcerans in Mosquitoes and March flies captured from endemic areas of Northern Queensland, Australia |
| Q33293328 | A synthetic entry to pladienolide B and FD-895 |
| Q28538259 | Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease |
| Q33983346 | Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. |
| Q28476689 | Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice |
| Q53469363 | Adhesion of the ulcerative pathogen Mycobacterium ulcerans to DACC-coated dressings. |
| Q37719029 | An Optimized Method for Extracting Bacterial RNA from Mouse Skin Tissue Colonized by Mycobacterium ulcerans |
| Q33196152 | Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone |
| Q28538249 | Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice |
| Q36063218 | Antibody-Mediated Neutralization of the Exotoxin Mycolactone, the Main Virulence Factor Produced by Mycobacterium ulcerans |
| Q92697590 | Antimicrobial activity of Mycobacteriophage D29 Lysin B during Mycobacterium ulcerans infection |
| Q37385024 | Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations |
| Q43170874 | Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. |
| Q28748563 | Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity |
| Q38994589 | Aquatic macroinvertebrate assemblages of Ghana, west Africa: Understanding the ecology of a neglected tropical disease |
| Q40591790 | Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment |
| Q36292804 | Assessing and managing wounds of Buruli ulcer patients at the primary and secondary health care levels in Ghana |
| Q46944299 | Associations between mycobacterium ulcerans and aquatic plant communities of West Africa: Implications for Buruli ulcer disease |
| Q33851427 | BCG-mediated protection against Mycobacterium ulcerans infection in the mouse |
| Q39075039 | Bacterial Signaling to the Nervous System through Toxins and Metabolites |
| Q26766446 | Bacterial Toxins as Pathogen Weapons Against Phagocytes |
| Q44630939 | Bacterial therapeutics |
| Q44220525 | Beware the Buruli ulcer |
| Q27670890 | Biochemical and Structural Study of the Atypical Acyltransferase Domain from the Mycobacterial Polyketide Synthase Pks13 |
| Q39027379 | Biochemical and genetic evidence for phospholipase C activity in Mycobacterium ulcerans |
| Q28486328 | Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA:AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II |
| Q38195645 | Biosynthesis of mycobacterial lipids by polyketide synthases and beyond |
| Q34010324 | Biosynthesis of polyketides in heterologous hosts |
| Q87036761 | Biosynthesis of the natural fluorophore legioliulin from legionella |
| Q59356163 | Buruli Ulcer in Sub-Saharan Africa |
| Q46241939 | Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans |
| Q59132198 | Buruli Ulcer: a Review of the Current Knowledge |
| Q34229628 | Buruli ulcer |
| Q58461875 | Buruli ulcer |
| Q21144731 | Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control |
| Q34594767 | Buruli ulcer (Mycobacterium ulcerans infection). |
| Q46809372 | Buruli ulcer - beyond the skin, impact on skeletal muscle |
| Q37387041 | Buruli ulcer disease: prospects for a vaccine |
| Q42553307 | Buruli ulcer, Central African Republic |
| Q96304671 | Buruli ulcer: The Efficacy of Innate Immune Defense May Be a Key Determinant for the Outcome of Infection With Mycobacterium ulcerans |
| Q46697036 | Buruli ulcer: a dynamic transversal research model performed through the international network of Pasteur Institutes |
| Q36497273 | Buruli ulcer: emerging from obscurity. |
| Q37349850 | Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans |
| Q57203196 | Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans |
| Q39611349 | Buruli ulcer: the third most common mycobacterial infection. |
| Q37010094 | CHEMICAL AND MINERALOGICAL CHARACTERISTICS OF FRENCH GREEN CLAYS USED FOR HEALING. |
| Q95362569 | Cell death at the cross roads of host-pathogen interaction in Mycobacterium tuberculosis infection |
| Q34193844 | Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination |
| Q42924367 | Characterization and identification of distinct Mycobacterium massiliense extracellular proteins from those of Mycobacterium abscessus |
| Q34880338 | Chemistry of mycolactones, the causative toxins of Buruli ulcer |
| Q35768998 | Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): Effect of Time-Delay to Diagnosis on Clinical Forms and Severe Phenotypes |
| Q36618316 | Clinical Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection |
| Q44420189 | Clinical considerations on Buruli ulcer employing two molecular tests for the detection of Mycobacterium ulcerans in 100 skin biopsies |
| Q37533905 | Clinical, microbiological and pathological findings of Mycobacterium ulcerans infection in three Australian Possum species |
| Q35145483 | Combined inflammatory and metabolic defects reflected by reduced serum protein levels in patients with Buruli ulcer disease |
| Q33714520 | Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans |
| Q28833171 | Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans |
| Q39501255 | Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence |
| Q50028007 | Comparative genomics shows Mycobacterium ulcerans migration and expansion has preceded the rise of Buruli ulcer in south-eastern Australia. |
| Q35033207 | Comparing genomes within the species Mycobacterium tuberculosis |
| Q34500901 | Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection |
| Q93127228 | Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls |
| Q34602038 | Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. |
| Q39656506 | Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts |
| Q21263166 | Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactones |
| Q34235687 | Detection of Mycobacterium ulcerans by the Loop-mediated Isothermal Amplification Method |
| Q34150159 | Detection of Mycobacterium ulcerans in the environment predicts prevalence of Buruli ulcer in Benin. |
| Q28472261 | Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue |
| Q35922743 | Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA. |
| Q28469338 | Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin |
| Q43777355 | Diethyl phthalate, a chemotactic factor secreted by Helicobacter pylori |
| Q45928623 | Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. |
| Q35549819 | Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease |
| Q33325502 | Distribution of Mycobacterium ulcerans in Buruli ulcer endemic and non-endemic aquatic sites in Ghana |
| Q37051036 | Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans |
| Q52671879 | Early trafficking events of Mycobacterium ulcerans within Naucoris cimicoides. |
| Q21144518 | Ecology and Transmission of Buruli Ulcer Disease: A Systematic Review |
| Q45194227 | Ecology and transmission of Mycobacterium ulcerans |
| Q28552524 | Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease |
| Q35917186 | Emerging aspects of Buruli ulcer. |
| Q34568947 | Emerging therapeutic targets in tuberculosis: post-genomic era. |
| Q64070135 | Environmental Variations in Mycobacterium ulcerans Transcriptome: Absence of Mycolactone Expression in Suboptimal Environments |
| Q38219419 | Epidemiology and management of Buruli ulcer |
| Q35689228 | Evidence for an intramacrophage growth phase of Mycobacterium ulcerans |
| Q41431702 | Evidences of the Low Implication of Mosquitoes in the Transmission of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer |
| Q37738682 | Evolutionary Thrift: Mycobacteria Repurpose Plasmid Diversity during Adaptation of Type VII Secretion Systems |
| Q33881961 | Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease |
| Q21092307 | First cultivation and characterization of mycobacterium ulcerans from the environment |
| Q36064228 | Functional Diversity as a New Framework for Understanding the Ecology of an Emerging Generalist Pathogen |
| Q33224239 | Gap, a mycobacterial specific integral membrane protein, is required for glycolipid transport to the cell surface |
| Q92094261 | Genome-wide association study of Buruli ulcer in rural Benin highlights role of two LncRNAs and the autophagy pathway |
| Q24681753 | Genomics of Actinobacteria: tracing the evolutionary history of an ancient phylum |
| Q39493114 | Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units |
| Q34779036 | Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon |
| Q24608268 | Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans |
| Q24673638 | Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F |
| Q34581754 | Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence |
| Q98726963 | High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice |
| Q37296425 | Highly stereoselective total synthesis of fully hydroxy-protected mycolactones A and B and their stereoisomerization upon deprotection |
| Q34396322 | Histopathologic features of Mycobacterium ulcerans infection |
| Q38157768 | History, biology and chemistry of Mycobacterium ulcerans infections (Buruli ulcer disease). |
| Q35036510 | How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains |
| Q35656072 | Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS) |
| Q39518871 | Immune response to infection with Mycobacterium ulcerans |
| Q33283728 | Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis |
| Q90603894 | In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model |
| Q35911339 | In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth |
| Q43168426 | Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia |
| Q34033119 | Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. |
| Q39413440 | Infiltrating leukocytes surround early Buruli ulcer lesions, but are unable to reach the mycolactone producing mycobacteria |
| Q53702000 | Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4. |
| Q27021065 | Inhibitors of Protein Translocation Across the ER Membrane |
| Q47228430 | Inhibitors of protein translocation across membranes of the secretory pathway: novel antimicrobial and anticancer agents. |
| Q37545814 | Insertion sequence element single nucleotide polymorphism typing provides insights into the population structure and evolution of Mycobacterium ulcerans across Africa |
| Q34769170 | Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis |
| Q34119520 | Interaction of mycobacterium ulcerans with mosquito species: Implications for transmission and trophic relationships |
| Q35919532 | Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice |
| Q38979254 | Investigation of wild-type and mycolactone-negative mutant Mycobacterium ulcerans on skeletal muscle: IGF-1 protects against mycolactone-induced muscle catabolism |
| Q39743356 | Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice |
| Q33613484 | Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease |
| Q55365530 | Laboratory confirmation of Buruli ulcer cases in Ghana, 2008-2016 |
| Q24641812 | Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans |
| Q37315680 | Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans |
| Q36002996 | Local Cellular Immune Responses and Pathogenesis of Buruli Ulcer Lesions in the Experimental Mycobacterium Ulcerans Pig Infection Model |
| Q36446126 | Local Heat Application for the Treatment of Buruli Ulcer: Results of a Phase II Open Label Single Center Non Comparative Clinical Trial |
| Q35790836 | Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection |
| Q46582749 | Localised Mycobacterium ulcerans infection in a cat in Australia |
| Q54338000 | Localised Mycobacterium ulcerans infection in four dogs. |
| Q28547936 | Locally Confined Clonal Complexes of Mycobacterium ulcerans in Two Buruli Ulcer Endemic Regions of Cameroon |
| Q64914067 | MAV_4644 Interaction with the Host Cathepsin Z Protects Mycobacterium avium subsp. hominissuis from Rapid Macrophage Killing. |
| Q34299710 | Macrophage cytokines: involvement in immunity and infectious diseases |
| Q40794641 | Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone. |
| Q48105775 | Membrane perturbing properties of toxin mycolactone from Mycobacterium ulcerans |
| Q36346380 | Metabolomic profiles delineate mycolactone signature in Buruli ulcer disease. |
| Q38384606 | Methods used in preclinical assessment of anti-Buruli ulcer agents: A global perspective |
| Q34630531 | Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease |
| Q57776721 | Modular total syntheses of mycolactone A/B and its [2H]-isotopologue |
| Q40399156 | Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin |
| Q43903644 | Molecular basis of bacterial virulence and survival within infected hosts and the environment |
| Q33960794 | Molecular epidemiologic evaluation of transmissibility and virulence of Mycobacterium tuberculosis |
| Q36264288 | Multiple Introductions and Recent Spread of the Emerging Human Pathogen Mycobacterium ulcerans across Africa |
| Q53826312 | Mycobacterial extracellular vesicles and host pathogen interactions. |
| Q37213915 | Mycobacteriosis in fishes: a review |
| Q36227714 | Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease |
| Q90110322 | Mycobacterium tuberculosis Sulfolipid-1 Activates Nociceptive Neurons and Induces Cough |
| Q28487575 | Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. |
| Q33758010 | Mycobacterium tuberculosis arrests host cycle at the G1/S transition to establish long term infection |
| Q34137695 | Mycobacterium tuberculosis in the post-genomic age. |
| Q35145362 | Mycobacterium ulcerans Fails to Infect through Skin Abrasions in a Guinea Pig Infection Model: Implications for Transmission |
| Q36205512 | Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates. |
| Q36074572 | Mycobacterium ulcerans causes minimal pathogenesis and colonization in medaka (Oryzias latipes): An experimental fish model of disease transmission |
| Q24514493 | Mycobacterium ulcerans cytotoxicity in an adipose cell model |
| Q33837366 | Mycobacterium ulcerans disease; Buruli ulcer |
| Q36034039 | Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia |
| Q45346929 | Mycobacterium ulcerans infection in two alpacas. |
| Q33740769 | Mycobacterium ulcerans infection. |
| Q38715292 | Mycobacterium ulcerans mycolactone interferes with adhesion, migration and proliferation of primary human keratinocytes and HaCaT cell line |
| Q34484489 | Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression |
| Q104609579 | Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine |
| Q57080463 | Mycobacterium ulceransinfection diagnosed by polymerase chain reaction |
| Q36733497 | Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation |
| Q64119264 | Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters |
| Q38695592 | Mycolactone cytotoxicity in Schwann cells could explain nerve damage in Buruli ulcer. |
| Q21090122 | Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs |
| Q33980141 | Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring |
| Q47137536 | Mycolactone displays anti-inflammatory effects on the nervous system. |
| Q30914398 | Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer |
| Q36594072 | Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study |
| Q38951193 | Mycolactone reveals the substrate-driven complexity of Sec61-dependent transmembrane protein biogenesis. |
| Q37500335 | Mycolactone subverts immunity by selectively blocking the Sec61 translocon. |
| Q27318699 | Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions |
| Q35949741 | Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection |
| Q37115277 | Mycolactone-mediated neurite degeneration and functional effects in cultured human and rat DRG neurons: Mechanisms underlying hypoalgesia in Buruli ulcer |
| Q34266843 | Mycolactones and Mycobacterium ulcerans disease |
| Q37170768 | Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria |
| Q36200942 | Natural products as mediators of disease. |
| Q87166461 | Natural products: Hunting microbial metabolites |
| Q55247742 | Naturally occurring a loss of a giant plasmid from Mycobacterium ulcerans subsp. shinshuense makes it non-pathogenic. |
| Q39516850 | Necrosis of lung epithelial cells during infection with Mycobacterium tuberculosis is preceded by cell permeation |
| Q34292327 | Necrotic death of Rhodococcus equi-infected macrophages is regulated by virulence-associated plasmids. |
| Q28267545 | Neglected tropical diseases |
| Q35088084 | Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer |
| Q46585361 | New approaches towards the synthesis of the side-chain of mycolactones A and B. |
| Q40282605 | Nontuberculous mycobacteria |
| Q36219941 | Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy |
| Q38180374 | Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens |
| Q33511900 | Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer |
| Q30484591 | Persistent association of Mycobacterium ulcerans with West African predaceous insects of the family belostomatidae |
| Q90398229 | Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review |
| Q34702499 | Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model |
| Q34108761 | Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. |
| Q33409842 | Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial |
| Q34238411 | Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: considerations for handling and storage |
| Q38180777 | Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer |
| Q24792373 | Principles of microbial alchemy: insights from the Streptomyces coelicolor genome sequence |
| Q36295353 | Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease) |
| Q34174558 | Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). |
| Q35623341 | Prospects for vaccine development against Buruli disease |
| Q28469147 | Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva |
| Q39580405 | Protective effect of a dewaxed whole-cell vaccine against Mycobacterium ulcerans infection in mice |
| Q24548647 | Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer |
| Q34016179 | Proteomic analysis of the action of the Mycobacterium ulcerans toxin mycolactone: targeting host cells cytoskeleton and collagen |
| Q58042832 | Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive Stress Signature |
| Q28552925 | RNA Aptamer That Specifically Binds to Mycolactone and Serves as a Diagnostic Tool for Diagnosis of Buruli Ulcer |
| Q33962755 | Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains |
| Q28537749 | Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection |
| Q38634493 | Recent advances: role of mycolactone in the pathogenesis and monitoring of Mycobacterium ulcerans infection/Buruli ulcer disease. |
| Q35782951 | Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. |
| Q28535119 | Regulation of mycolactone, the Mycobacterium ulcerans toxin, depends on nutrient source |
| Q51410365 | Regulation of the Cell Biology of Antigen Cross-Presentation. |
| Q38579126 | Revisiting Buruli ulcer |
| Q36033978 | Risk factors for Mycobacterium ulcerans infection, southeastern Australia |
| Q38258019 | Roles of bacterial membrane vesicles. |
| Q33715059 | Scalable and efficient synthesis of the mycolactone core |
| Q33871043 | Seasonal Pattern of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer, in the Environment in Ghana |
| Q38692382 | Sec61 blockade by mycolactone inhibits antigen cross-presentation independently of endosome-to-cytosol export |
| Q28487505 | Secondary Bacterial Infections of Buruli Ulcer Lesions Before and After Chemotherapy with Streptomycin and Rifampicin |
| Q33988898 | Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? |
| Q39162386 | Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria |
| Q37103259 | Secondary necrosis in multicellular animals: an outcome of apoptosis with pathogenic implications. |
| Q36229394 | Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone |
| Q33745230 | Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics |
| Q35644283 | Shaping mycolactone for therapeutic use against inflammatory disorders |
| Q86055703 | Short Convergent Synthesis of the Mycolactone Core Through Lithiation-Borylation Homologations |
| Q90739257 | Signaling Natural Products from Human Pathogenic Bacteria |
| Q52647372 | Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria. |
| Q57080441 | Skin ulceration: what lies beneath |
| Q90057158 | Skin-specific antibodies neutralizing mycolactone toxin during the spontaneous healing of Mycobacterium ulcerans infection |
| Q35857386 | Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model |
| Q39746007 | Structural and functional cellular changes induced by Burkholderia pseudomallei rhamnolipid. |
| Q27684461 | Structure, Biochemistry, and Inhibition of Essential 4′-Phosphopantetheinyl Transferases from Two Species of Mycobacteria |
| Q34654293 | Structure-activity relationship studies on the macrolide exotoxin mycolactone of Mycobacterium ulcerans |
| Q105307675 | Studies toward Unique Mycolactone Macrolides from Mycobacterium ulcerans |
| Q37062702 | Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans |
| Q54244186 | Surgery for Buruli ulcer in the antibiotic era. |
| Q44682716 | Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. |
| Q46201652 | Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. |
| Q42372966 | Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms |
| Q34084883 | Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors |
| Q33733563 | Synthesis and structure assignment of the minor metabolite arising from the frog pathogen Mycobacterium liflandii |
| Q37395656 | Synthesis and structure of mycolactone E isolated from frog mycobacterium |
| Q58479648 | Synthesis of the Conjugated Tetraene Acid Side Chain of Mycolactone E by Suzuki-Miyaura Cross-Coupling Reaction of Alkenyl Boronates |
| Q57776726 | Synthetic strategies towards mycolactone A/B, an exotoxin secreted by Mycobacterium ulcerans |
| Q42906162 | Synthetic studies on the mycolactone core |
| Q36582845 | Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms |
| Q60020041 | Targeting the Mycobacterium ulcerans cytochrome bc:aa for the treatment of Buruli ulcer |
| Q38569307 | The Buruli Ulcer |
| Q57229660 | The Genus Mycobacterium--Medical |
| Q28534813 | The cell wall-associated mycolactone polyketide synthases are necessary but not sufficient for mycolactone biosynthesis |
| Q41469222 | The chemistry and biology of mycolactones. |
| Q61805401 | The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model |
| Q36583785 | The evolving story of Mycobacterium tuberculosis clade members detected in fish |
| Q61813591 | The extracellular matrix of mycobacterial biofilms: could we shorten the treatment of mycobacterial infections? |
| Q89886649 | The immunology of other mycobacteria: M. ulcerans, M. leprae |
| Q44814557 | The local immune response in ulcerative lesions of Buruli disease. |
| Q28541949 | The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER |
| Q28659329 | The phosphopantetheinyl transferases: catalysis of a post-translational modification crucial for life |
| Q48269589 | The potent effect of mycolactone on lipid membranes. |
| Q44738439 | Topical exposure to exogenous ultraviolet-irradiated urocanic acid enhances Mycobacterium ulcerans infection in a Crl:IAF(HA)-hrBR hairless guinea-pig model of Buruli ulcer disease |
| Q36076322 | Total Synthesis of Mycolactones A and B. |
| Q35625819 | Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? |
| Q35533091 | Tropical Plant Extracts Modulating the Growth of Mycobacterium ulcerans |
| Q47159580 | Tuberculosis: Just the FAQs |
| Q78816691 | Ultraviolet radiation enhances both the nodular and ulcerative forms of Mycobacterium ulcerans infection in a Crl:IAF(HA)-hrBR hairless guinea pig model of Buruli ulcer disease |
| Q64958683 | Understanding the Significance of Biochemistry in the Storage, Handling, Purification, and Sampling of Amphiphilic Mycolactone. |
| Q44353323 | Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans |
| Q35746584 | Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease. |
| Q38972659 | Use of the immunodominant 18-kilodalton small heat shock protein as a serological marker for exposure to mycobacterium ulcerans |
| Q34483614 | Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection |
| Q35915755 | Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. |
| Q39407596 | What does detection of Mycobacterium ulcerans DNA in the margin of an excised Buruli ulcer lesion tell us? |
| Q35234856 | Whole Genome Comparisons Suggest Random Distribution of Mycobacterium ulcerans Genotypes in a Buruli Ulcer Endemic Region of Ghana |
Search more.